Livagen
Research OnlyA synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.
KED · Lys-Glu-Asp · Hepatogen
Mostly preclinical · 2 human studies
- Preclinical
- 67%
- Clinical
- 17%
Based on 12 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 21 (1A 9: best human evidence is an uncontrolled ex-vivo lymphocyte-chromatin observation in senile subjects, Khavinson 2004 PMID:15085253 — a documented human observation, not a clinical outcome study; 1B 3 high RoB single-group; 1C 2 human N<50; 1D 3 indirect surrogate, not a liver outcome in the target population; 1E 4 modest single-group rat organotypic/animal program PMID:11713572, PMID:12096446). Mechanism 30 (2A 10 target only inferred as DNA/histone interaction with no measured binding; 2B 8 pathway largely hand-wavy; 2C 4 no dose-response; 2D 8 in-vivo mammalian organotypic models). Plausibility 51 (3A 14 liver-benefit claim is a large leap from a gene-modulation surrogate with unproven intermediate links; 3B 16 coherent-to-neutral with tissue-specificity bioregulator biology; 3C 12 same-class Khavinson peptides show analogous tissue-specific effects; 3D 9 spans regeneration/antioxidant/anti-aging beyond a single tightly-scoped claim). Global Coverage 16 (4A 5 all from the Khavinson / St. Petersburg group; 4B 5 single country/institute; 4C 6 <5 Livagen-specific studies, narrow; 4D 0 research-only, no regulator). Community Experience 25 (5A 4 negligible documented use; 5B 7 limited Livagen-specific track record; 5C 4 no reports to assess consistency; 5D 10 no recurring adverse signal). Overall round(0.30*21 + 0.20*30 + 0.20*51 + 0.15*16 + 0.15*25) = 29, preliminary. Effectiveness not-established: no quantified human efficacy estimate and no meaningful community effect signal (communityNotes report no user reports). Note: Kuznik 2020 review PMID:32362099 describes KEDA (Lys-Glu-Asp-Ala tetrapeptide) alongside the KED tripeptide — citations are real and Livagen-relevant.
The proposed mechanisms of Livagen are based entirely on Russian bioregulator research. No independent Western validation or human mechanistic data from controlled trials exists.
How It Works (Simplified)
Livagen targets liver function through gene expression modulation and related pathways:
Claimed to interact with DNA in hepatocytes, modulating expression of genes involved in liver function and regeneration.
Proposed to decondense heterochromatin in liver cells, potentially reactivating genes that become silenced with age or damage.
Cell culture studies suggest protection of hepatocytes from toxic insults, though mechanism is not fully characterized.
Russian studies suggest upregulation of hepatic antioxidant defenses, reducing oxidative damage in liver tissue.
Note: These pathways are based on Russian bioregulator theory. The specific molecular targets and mechanisms have not been independently validated.
Important Limitations
- 100% of research from Russian institutions (primarily St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any findings
- No controlled human clinical trials have been conducted
- Specific molecular targets and binding sites not characterized
- Pharmacokinetics, bioavailability, and metabolism in humans unknown
- Translation from cell culture to human liver benefits is unconfirmed
- Regulatory status: Not approved anywhere; research compound only
Based on preclinical data: Initial effects on hepatic gene expression may begin. Cell culture studies suggest gene modulation occurs within days of treatment. No human pharmacokinetic data available.
PMID:11713572Continued treatment in animal models shows progressive hepatoprotective effects. Chromatin remodeling and epigenetic changes may develop in liver tissue. Russian protocols typically involve treatment courses of several weeks.
PMID:32362099Extended treatment periods in animal studies associated with improved liver function markers. Russian protocols often involve cyclical treatment patterns. Human response timeline is unknown.
PMID:12096446Long-term effects are extrapolated from animal studies. Russian bioregulator protocols typically recommend cyclical treatment courses. Human pharmacokinetics, optimal duration, and long-term effects are completely uncharacterized.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct targets - epithalon for telomerase/pineal, Livagen for hepatic gene expression. No known direct interactions.
Vilon
CompatibleBoth short peptide bioregulators from Russian research - Vilon targets thymus/immune function, Livagen targets liver. May be used in combination protocols.
Thymalin
CompatibleBoth Russian bioregulator peptides - thymalin for immune modulation, Livagen for hepatic support. Different tissue targets suggest compatibility.
BPC-157
CompatibleDifferent mechanisms for tissue support - BPC-157 broadly cytoprotective, Livagen specifically hepatic-focused. No known contraindications.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Livagen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.